6.83
전일 마감가:
$7.33
열려 있는:
$7.17
하루 거래량:
2.31M
Relative Volume:
1.21
시가총액:
$1.16B
수익:
$177.28M
순이익/손실:
$-195.24M
주가수익비율:
-5.097
EPS:
-1.34
순현금흐름:
$-114.54M
1주 성능:
-12.66%
1개월 성능:
-18.69%
6개월 성능:
+50.11%
1년 성능:
+184.58%
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
명칭
Adaptive Biotechnologies Corp
전화
206-659-0067
주소
1165 EASTLAKE AVE E, SEATTLE, WA
ADPT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ADPT
Adaptive Biotechnologies Corp
|
6.83 | 1.16B | 177.28M | -195.24M | -114.54M | -1.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-21 | 업그레이드 | Goldman | Neutral → Buy |
2023-07-05 | 재개 | JP Morgan | Overweight |
2023-01-05 | 개시 | Scotiabank | Sector Outperform |
2022-12-21 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2022-08-25 | 개시 | Credit Suisse | Underperform |
2022-06-03 | 개시 | Piper Sandler | Neutral |
2022-02-16 | 재확인 | BTIG Research | Buy |
2022-02-16 | 재확인 | BofA Securities | Buy |
2022-02-16 | 재확인 | Goldman | Neutral |
2022-02-16 | 재확인 | JP Morgan | Overweight |
2021-10-15 | 재개 | Cowen | Outperform |
2021-03-03 | 다운그레이드 | Goldman | Buy → Neutral |
2020-10-08 | 재개 | BTIG Research | Buy |
2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
2020-06-03 | 개시 | Goldman | Buy |
2019-07-23 | 개시 | BTIG Research | Buy |
2019-07-22 | 개시 | BofA/Merrill | Buy |
2019-07-22 | 개시 | Cowen | Outperform |
2019-07-22 | 개시 | Goldman | Neutral |
2019-07-22 | 개시 | Guggenheim | Buy |
2019-07-22 | 개시 | William Blair | Outperform |
모두보기
Adaptive Biotechnologies Corp 주식(ADPT)의 최신 뉴스
Insider ROBINS HARLAN S sells 1,698 of Adaptive Biotechnologies Corp [ADPT] Stock - knoxdaily.com
JPMorgan Chase & Co. Lowers Stock Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Alliancebernstein L.P. Sells 1,890 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Federated Hermes Inc. Reduces Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Franklin Resources Inc. Invests $443,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 | ADPT Stock News - GuruFocus
Corebridge Financial Inc. Has $345,000 Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 - The Manila Times
25,800 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by KLP Kapitalforvaltning AS - Defense World
Adaptive Biotechnologies' Mantle Cell Lymphoma Test Receives Expanded Medicare Coverage - MarketScreener
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma - The Manila Times
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Guess, Tesla, Nvidia And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Swiss National Bank Takes $1.22 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Proficio Capital Partners LLC Takes Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Corp: Analyzing ADPT Stock Trends - investchronicle.com
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 12-Month HighShould You Buy? - MarketBeat
Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 - Investing.com India
Charles Schwab Investment Management Inc. Acquires 39,831 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies stock hits 52-week high at $8.95 By Investing.com - Investing.com Australia
Adaptive Biotechnologies stock hits 52-week high at $8.95 - Investing.com
Amundi Boosts Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up – What’s Next? - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World
Bank of New York Mellon Corp Has $2.18 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Gains Following Goldman Sachs Upgrade, Share Climb 6% Near Friday Close - MarketScreener
Analyst Expectations For Adaptive Biotechnologies's Future - Benzinga
Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday - Benzinga
Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8 - Marketscreener.com
Goldman Sachs lifts Adeptus Biotech stock rating to Buy, target to $9 - Investing.com
Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March - Insider Monkey
10 Stocks Insiders Are Selling In March - Insider Monkey
Proficio Capital Partners LLC Takes $93,000 Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World
Adaptive Biotechnologies director sells shares worth $70,500 By Investing.com - Investing.com Canada
Adaptive Biotechnologies director sells shares worth $70,500 - Investing.com India
Adaptive Biotechnologies director sells shares worth $402,270 - Investing.com
Adaptive Biotechnologies Executives Sell Shares - TradingView
Minimal Residual Disease Market Expected to rise, 2032 | Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, Amgen Inc., expected to boost the market - Barchart
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma - The Manila Times
US Bancorp DE Sells 43,819 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Revolutionary 7x Sensitivity Boost: Adaptive's New Cancer Detection Test Transforms Lymphoma Monitoring - Stock Titan
Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells $819,109.98 in Stock - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% on Insider Selling - Defense World
Adaptive Biotechnologies director sells $124,372 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CEO Chad Robins sells $1.6 million in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Purchases Shares of 143,444 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Corp (ADPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):